OOIR: Observatory of International Research

Papers

(The H4-Index of Oncologist is 35. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
37 Cost-effectiveness of treatment sequences with front-line nivolumab+ipilimumab therapy vs immuno-oncology+tyrosine kinase inhibitor therapies in intermediate/poor-risk metastatic renal cell carcino	183
18 Unraveling the Impact of Tumor Microenvironment on Immunotherapy Response/Resistance in Human Sarcomatoid Clear Cell Renal Cell Carcinoma: Insights from a Novel Mouse Model	117
55 Influence of gender on immunosurveillance in a novel mouse model of clear cell renal cell carcinoma	112
Clinical ethics consultation services: public-facing information on NCI-designated cancer center websites	102
Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer	86
Surgical De-Escalation in Medullary Thyroid Cancer: A Commentary	77
Communicating the diagnosis of a hematological neoplastic disease to patients’ minor children: a multicenter prospective study	66
Correction to: Physician Payments from Pharmaceutical Companies Related to Cancer Drugs	66
Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy	65
The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)	64
9Characterizing carbonic anhydrase 9 and HIF-2α RNA expression in clear cell renal cell carcinoma (ccRCC)	56
46Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC)	56
Determining the Cancer Center priorities at the Wilmot Cancer Institute: A proposed framework informed by an academic-community collaborative approach	49
IUC23530-78 Diagnostic value, safety, and patient-reported outcomes of total free-hand LATP biopsy technique	47
Calls to action on lung cancer management and research	47
IUC24430-78 Lesion-level meta-diagnostic of cognitive vs fusion MRI-targeted biopsy in PCa: PRECISION-2 insights	46
IUC24025-78 Early results of moderate hypofractionated radiotherapy implementation for localized prostate cancer patients in Vietnam	45
Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer	44
Palliative Rehabilitation in Acute Inpatient Rehabilitation: Prognostic Factors and Functional Outcomes in Patients with Cancer	43
GBAS Regulates the Proliferation and Metastasis of Ovarian Cancer Cells by Combining with eEF1A1	42
Contextualizing results of randomized trials in smoldering myeloma	40
A blueprint for creating an early-onset colorectal cancer program based on experiences from seven clinical centers across the United States and Canada	40
ALK-positive adult histiocytosis with a TFG-ALKfusion gene	40
Implementation of neoadjuvant immunotherapy in stage III melanoma: a modified Delphi consensus study in a European-accredited cancer center in Ireland	38
Correction to: Phase Ib/II Study of Biweekly TAS-102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)	38

Classification of NK-large granular lymphocytic leukemia by CD56 expression	38
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay	38
8 Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial	37
Neoadjuvant rectal-tumor regression grade combined score as surrogate endpoint for disease-free survival in locally advanced rectal cancer patients after neoadjuvant chemoradiotherapy	37
Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation	36
“Game Changer”: Health Professionals’ Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management	36
Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma	36
Clinical actionability of BRCA2 alterations in uterine leiomyosarcoma: a molecular tumor board case report and a cBioPortal comprehensive analysis	36
ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data	35
Patients’ and caregivers’ perspectives on preparedness for and experience with chimeric antigen receptor T-cell therapy	35